Vitamin C delivers encouraging outcomes in early-stage COVID-19 patients

10 May 2021 | Monday | Analysis

Studies were conducted at a government hospital in Coimbatore over 4 months on 400 COVID-19 positive patients
Image Source : shutterstock

Image Source : shutterstock

Studies published in the Indian Journal of Basic and Applied Medical Research prove Vitamin C’s effectiveness on COVID-19 patients. Studies were conducted at a government hospital in Coimbatore over 4 months on 400 COVID-19 positive patients with consent to understand the impact of high dose of vitamin C given via Liposomal Vitamin C drink and Vitamin-C tablets.

It also focused on COVID-19 induced neurocognitive dysfunction & cytokine storm.

A separate study was also conducted on 162 patients with consent to understand the impact of a high dose of Vitamin C on anxiety and depression. It also rendered positive results.

The study rendered positive results and paves way for Mirakle- a liposomal vitamin C rich drink to be a remedy for this global malady.

The results of these different studies are as follows:

  • Two consecutive negative results were confirmed in 94 per cent of patients on high dose oral liposomal Vitamin-C.
  • High dose intravenous as well as oral liposomal Vitamin-C is more effective in protection and recovery from COVID-19 induced neuro-cognitive dysfunction.
  • With available standard protocols, high dose Vitamin-C intravenous or liposomal oral Vitamin C is giving promising results in bringing down CRP and Ferritin levels providing a potential signal of benefit in oxygenation and even Interleukin- 6 or IL-6. More research is required to optimize the doses and duration of administration.
  • Results showed that Vitamin C reduced anxiety levels and led to higher plasma Vitamin-C concentration. The mean heart rates were also significantly different between high dose Vitamin C group and control group.

The four studies have been acknowledged and their collective results received positive response from doctors in the US.

In their acknowledgement, Ronald Hunninghake, MD, Chief Medical Officer & Dr Thomas E. Levy, MD, JD, Consultant at Riordan Clinic, Wichita, Kansas, USA have said, “The new liposomal Vitamin C drink promises to be a breakthrough for early-stage COVID-19. By curtailing the early stages of scurvy, the virus-induced runaway train of inflammation, coagulation, and pulmonary and blood invasion...just will not happen!  This strategy is one of our best new hopes for resolving this awful pandemic.”


Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in